# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and susta...
HC Wainwright & Co. analyst Emily Bodnar maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and raises the price...
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(1.08) per share. This is a 49.77 percent increase over los...
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating a...